Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (7748)	3/18/2000 7:08:00 PM
From: Ward Knutson	Read Replies (1) \| Respond to of 9719

V1, Taxol and all other front-line therapy agents have dose-limiting side effects. This drug has a selective uptake action that differentiates it from today's cytotoxic agents. I firmly believe you will, as you see further results, see that this drug is capable of finding a role even more significant than that of the several hundred million dollars "salvage" therapy indications could bring. Take notice of the Prostate study, in this patient population the drug has shown to be very well tolerated. This implies that those yet to be heavily pre-treated (as would be the case as front-line therapy) with other chemo agents (Prostate patients are handled front-line by hormonal therapies) can be, and have been, treated with significant dosing over numerous courses of therapy of MGI-114 exhibiting both a high degree of efficacy and safety. Too early to be certain, but I encourage you to look deeply into the mounting body of supporting data and research supporting MGI-114. <<It is critical to understand MGI 114's mechanism of action so that analogs can be derived that are more specific and have fewer dose limiting side effects.>> Already in progress, in fact there are currently at least nine analogs at the NCI under pre-clinical evaluation - all have shown significant anti-tumor activity. MGI has stated as a goal for 2000 to identify at least one of these to advance in the development process. This will be an interesting AACR Presentation: Sunday, April 2, 2000 Presidential Address, "Pancreatic Cancer: New Targets, New Treatments" Daniel D. Von Hoff 8:00 - 9:00 a.m. Ward